LONDON, March 1, 2016 /PRNewswire/ -- Smith & Nephew
(NYSE:SNN; LSE:SN), the global medical technology business, is
showcasing the new REDAPT™ Revision Acetabular Fully Porous Cup
with CONCELOC™ Technology at this week's American Academy of
Orthopaedic Surgeons (AAOS) Annual Meeting in Orlando.
The new REDAPT cup is designed for use in revision cases where
compromised bone makes implant fixation and stability more
difficult. To allow ingrowth, an additive, or 3D,
manufacturing process is used to produce an entirely porous implant
that mimics the structure of cancellous bone and new variable-angle
locking screws can be used to enhance implant stability and
minimize micromotion after surgery.
"We're excited about the creative possibilities this new
manufacturing process holds for surgeons and their patients," said
Mike Donoghue, Vice President of
Global Reconstruction at Smith & Nephew. "Bringing to market a
3D-printed titanium acetabular cup for difficult revision
procedures is just one example of the potential of this remarkable
technology."
The CONCELOC Advanced Porous Titanium technology is an
alternative to external porous coatings, such as sintered beads or
fiber mesh used in other uncemented implants, to allow bone
ingrowth securing the implant in place.
Successful fixation of a porous implant requires that the
implant remains in steady, stationary contact with the bone as it
heals and new bone grows. For this reason, the new REDAPT cup also
uses the new REDAPT Variable Angle Locking Screws, which work
within the implant's unique geometry to provide both compression
and a rigid construct to the acetabular shell, as well as
traditional, non-locking screws.
"This fully porous cup gives surgeons flexibility in ways that
simply weren't possible before," said Craig
Della Valle, MD, Professor of Orthopaedic Surgery at
Rush University Medical Center in
Chicago, who participated on the
surgeon design team for the new REDAPT cup. "The locking screws,
screw-in trials, purpose-built liners and screw hole patterns
optimized for hard-to-access areas really set it apart during a
revision procedure. This cup builds on good technology and turns it
into something spectacular."
Smith & Nephew received Food and Drug Administration 510(k)
clearance for the REDAPT Revision Acetabular Fully Porous Cup with
CONCELOC Technology in November 2015.
It is currently available in select sites in the US and can be seen
this week at the Smith & Nephew booth (booth 1945) at the AAOS
Annual Meeting.
About 3D manufacturing
The 3D manufacturing process used to build each new REDAPT cup
begins by precisely aiming a laser onto a thin layer of titanium
(Ti-6Al-4V) powder. The heat generated by the laser fuses the
powder together, building upward, layer-by-layer, until a fully
formed titanium implant is produced. This manufacturing method
allows for complex design geometries that would be difficult,
expensive or impossible to achieve with traditional manufacturing
methods. For example, solid reinforcements can be built directly
into the porous structure to provide extra strength in precise
locations.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2015 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith & Nephew. Certain
marks registered US Patent and Trademark Office.
Photo - http://photos.prnewswire.com/prnh/20160229/338792
Logo - http://photos.prnewswire.com/prnh/20131030/CL06769LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/smith--nephew-unveils-its-first-3d-printed-titanium-hip-implant-1-march-2016-300228331.html
SOURCE Smith & Nephew